title: BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.
abstract: Tumour necrosis factor alpha (TNF-α) is an inflammatory cytokine with a wide spectrum of biological activity, including angiogenesis. B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are members of the TNF-α family. Vascular endothelial growth factor (VEGF), on the other hand, is one of the most characteristic pro-angiogenic cytokines produced by multiple cell types in multiple myeloma (MM). We have analysed BAFF and APRIL concentrations in parallel with pro-angiogenic cytokines in serum and trephine biopsy, and the bone marrow microvascular density (MVD) in 50 patients with newly diagnosed IgG MM and 24 healthy volunteers. The study showed statistically higher concentrations of BAFF, APRIL and TNF-α, as well as VEGF and its receptor, in MM patients compared to healthy volunteers and patients in advanced stages of the disease. A statistically positive correlation between the concentration of TNF-α and the expression of VEGF was demonstrated, and so was a positive link between BAFF, APRIL, MVD and lactate dehydrogenase (LDH). Furthermore, we observed a significant decrease in all studied cytokines after anti-angiogenic therapy, with meaningful differences between responders (at least partial remission) and patients with stable disease. It was also established that APRIL, but not BAFF, correlated with pro-angiogenic cytokines such as VEGF with its receptor, MVD and syndecan-1. Finally, our results showed that serum BAFF and APRIL levels could be useful biomarkers of MM disease activity and its progression which suggests that APRIL could be a possible novel therapeutic target in MM.
authors.affiliation: Department of Haematology, Medical University of Bialystok, 24a Sklodowskiej-Curie, Bialystok, 15-276, Poland, lbolkun@gmail.com.
authors.forename: L
authors.initials: L
authors.lastname: Bolkun
authors.forename: D
authors.initials: D
authors.lastname: Lemancewicz
authors.forename: E
authors.initials: E
authors.lastname: Jablonska
authors.forename: A
authors.initials: A
authors.lastname: Kulczynska
authors.forename: U
authors.initials: U
authors.lastname: Bolkun-Skornicka
authors.forename: J
authors.initials: J
authors.lastname: Kloczko
authors.forename: J
authors.initials: J
authors.lastname: Dzieciol
mesh_terms: D000328:Adult; D000368:Aged; D053264:B-Cell Activating Factor / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis; D009389:Neovascularization, Pathologic / Q000097:blood* / Q000175:diagnosis; D016037:Single-Blind Method; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D053264:B-Cell Activating Factor; D015415:Biomarkers; C505719:TNFSF13B protein, human; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; D014409:Tumor Necrosis Factor-alpha